Biomarker study of pembrolizumab in patients with advanced rare cancers.

Naing A, Li X, Wang Q, Tian XJ, Sabir S, Bhosale PR, Derbala MH, Stephen B, Xu M, Hajjar J, Gurses SA, Yang Y, Momin HA, Wistuba II, Alshawa A, Shaw KR, Zarifa A, Singh G, Pandurengan RK, Raso GM, Parra ER, Song J, Mohammad MM, Rodon Ahnert J, Fu S, Subbiah V, Piha-Paul SA, Wang J, Woodman SE, Meric-Bernstam F

Open source

DOI: 10.1016/j.xcrm.2026.102827
Published: 2026 Jun 16
Container: Cell reports. Medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.xcrm.2026.102827,
  title = {Biomarker study of pembrolizumab in patients with advanced rare cancers.},
  author = {Naing A and Li X and Wang Q and Tian XJ and Sabir S and Bhosale PR and Derbala MH and Stephen B and Xu M and Hajjar J and Gurses SA and Yang Y and Momin HA and Wistuba II and Alshawa A and Shaw KR and Zarifa A and Singh G and Pandurengan RK and Raso GM and Parra ER and Song J and Mohammad MM and Rodon Ahnert J and Fu S and Subbiah V and Piha-Paul SA and Wang J and Woodman SE and Meric-Bernstam F},
  year = {2026},
  journal = {Cell reports. Medicine},
  doi = {10.1016/j.xcrm.2026.102827},
  url = {https://doi.org/10.1016/j.xcrm.2026.102827}
}

RIS

TY  - JOUR
TI  - Biomarker study of pembrolizumab in patients with advanced rare cancers.
AU  - Naing A
AU  - Li X
AU  - Wang Q
AU  - Tian XJ
AU  - Sabir S
AU  - Bhosale PR
AU  - Derbala MH
AU  - Stephen B
AU  - Xu M
AU  - Hajjar J
AU  - Gurses SA
AU  - Yang Y
AU  - Momin HA
AU  - Wistuba II
AU  - Alshawa A
AU  - Shaw KR
AU  - Zarifa A
AU  - Singh G
AU  - Pandurengan RK
AU  - Raso GM
AU  - Parra ER
AU  - Song J
AU  - Mohammad MM
AU  - Rodon Ahnert J
AU  - Fu S
AU  - Subbiah V
AU  - Piha-Paul SA
AU  - Wang J
AU  - Woodman SE
AU  - Meric-Bernstam F
PY  - 2026
JO  - Cell reports. Medicine
DO  - 10.1016/j.xcrm.2026.102827
UR  - https://doi.org/10.1016/j.xcrm.2026.102827
ER  -

APA

A, N., X, L., Q, W., XJ, T., S, S., PR, B., MH, D., B, S., M, X., J, H., SA, G., Y, Y., HA, M., II, W., A, A., KR, S., A, Z., G, S., RK, P., GM, R., ER, P., J, S., MM, M., J, R. A., S, F., V, S., SA, P., J, W., SE, W., & F, M. (2026). Biomarker study of pembrolizumab in patients with advanced rare cancers.. Cell reports. Medicine. https://doi.org/10.1016/j.xcrm.2026.102827

Source records

pubmed · retrieved 2026-09-25T16:36:54.433Z